Q2 2026 Earnings

EX-99.1 2 a2026q2exhibit991.htm EX-99.1 Document Exhibit 99.1 Media contact: [email protected] Investor contact: [email protected] For immediate release Johnson & Johnson reports Q2 2026 results, raises 2026 outlook • 2026 Second-Quarter reported sales growth of 6.6% to $25.3 Billion with operational growth of 5.6%* and adjusted operational growth of 5.7%* • 2026 Second-Quarter earnings per share (EPS) of $2.27 and adjusted EPS* of $2.90 • Strong operational performance results in the Company increasing 2026 guidance with estimated reported sales of $101.1 Billion or 7.3% at the midpoint, and increasing adjusted EPS* guidance by $0.13 to $11.68 or 8.2% at the midpoint. The adjusted operational EPS* is increasing by $0.18 to $11.58 or 7.3% at the midpoint • Advancing significant innovation for patients with approvals of TREMFYA to inhibit the progression of structur...